Agenix Limited is an Australian-based biotechnology drug and diagnostic development company working to bring a new drug for hepatitis B called AGX-1009 to market in China. The company is also developing a new diagnostic called Thromboview, a radio-labelled monoclonal antibody imaging agent. The compound has complted two Phase II clinical trials aimed at showing its ability to diagnose patients indicated for suspected acute pulmonary embolism, with a positive D-dimer blood test or moderate to high pre test probability of pulmonary embolism.
AGX 1009, a reverse transcriptase inhibitor (NtRTI) prodrug of tenofovir, for which a clinical trial agreement to begin a Phase I clinical trial in China will be filed with China's State Food & Drug Administration in 2012.
Agenix Limited is an Australian-based biotechnology drug and diagnostic development company working to bring a new drug for hepatitis B called AGX-1009 to market in China. The company is also developing a new diagnostic called Thromboview, a radio-labelled monoclonal antibody imaging agent. The compound has complted two Phase II clinical trials aimed at showing its ability to diagnose patients indicated for suspected acute pulmonary embolism, with a positive D-dimer blood test or moderate to high pre test probability of pulmonary embolism.
AGX 1009, a reverse transcriptase inhibitor (NtRTI) prodrug of tenofovir, for which a clinical trial agreement to begin a Phase I clinical trial in China will be filed with China's State Food & Drug Administration in 2012.